470 related articles for article (PubMed ID: 29194866)
1. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with severe hemophilia A.
Huang K; Zhen Y; Li G; Wu X; Wu R; Chen Z
Haemophilia; 2021 May; 27(3):e340-e346. PubMed ID: 33645868
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A.
Huang K; Zhen Y; Li G; Wu X; Chen Z; Wu R
Haemophilia; 2021 Jul; 27(4):e450-e457. PubMed ID: 34015176
[TBL] [Abstract][Full Text] [Related]
5. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
[TBL] [Abstract][Full Text] [Related]
6. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT
Mingot-Castellano ME; Parra R; Núñez R; Martorell M
Haemophilia; 2018 Sep; 24(5):e338-e343. PubMed ID: 30028549
[TBL] [Abstract][Full Text] [Related]
7. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
Mullins ES; Stasyshyn O; Alvarez-Román MT; Osman D; Liesner R; Engl W; Sharkhawy M; Abbuehl BE
Haemophilia; 2017 Mar; 23(2):238-246. PubMed ID: 27891721
[TBL] [Abstract][Full Text] [Related]
8. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
9. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq
Dargaud Y; Negrier C; Rusen L; Windyga J; Georgiev P; Bichler J; Solomon C; Knaub S; Lissitchkov T; Klamroth R
Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.
Chen ZP; Li PJ; Li G; Tang L; Zhen YZ; Wu XY; Cheng XL; Luke KH; Blanchette VS; Poon MC; Ding QL; Wu RH
Chin Med J (Engl); 2018 Aug; 131(15):1780-1785. PubMed ID: 29848837
[TBL] [Abstract][Full Text] [Related]
11. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
Srichumpuang C; Rakmanotham A; Moonla C; Sosothikul D
Orphanet J Rare Dis; 2024 Mar; 19(1):135. PubMed ID: 38532451
[TBL] [Abstract][Full Text] [Related]
12. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
[TBL] [Abstract][Full Text] [Related]
13. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
[TBL] [Abstract][Full Text] [Related]
14. PK-guided personalized prophylaxis with Nuwiq
Lissitchkov T; Rusen L; Georgiev P; Windyga J; Klamroth R; Gercheva L; Nemes L; Tiede A; Bichler J; Knaub S; Belyanskaya L; Walter O; Pasi KJ
Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Individualized Preventive Treatment of Patients with Severe Hemophilia A Guided by Multiple Clinical Parameters and Pharmacokinetics.
Wang Y; Yang Q; Zheng L; Wang X; Jiang W; Lu L; Yan L; Zhang M; Chen L
Acta Haematol; 2022; 145(4):354-361. PubMed ID: 34879368
[TBL] [Abstract][Full Text] [Related]
16. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
[TBL] [Abstract][Full Text] [Related]
17. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
Collins PW; Blanchette VS; Fischer K; Björkman S; Oh M; Fritsch S; Schroth P; Spotts G; Astermark J; Ewenstein B;
J Thromb Haemost; 2009 Mar; 7(3):413-20. PubMed ID: 19143924
[TBL] [Abstract][Full Text] [Related]
18. Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A.
Huang K; Wang Y; Zhen Y; Li G; Wu X; Zhang N; Chen Z; Wu R
Thromb Res; 2022 May; 213():71-77. PubMed ID: 35305529
[TBL] [Abstract][Full Text] [Related]
19. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
[TBL] [Abstract][Full Text] [Related]
20. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
